Abstract
Background: Privileged structures are potentially able to bind to a diverse range of biologically important proteins with high affinities, thus benefiting the discovery of novel bioactive compounds. 1,2-Benxisoxazole derivatives can be such important types of “privileged structures” possessing a rich diversity of biological properties especially in the area of CNS disorders. Methods: This review seeks to explore the most significant examples of 1,2-benzisoxazoles as privileged structures in terms of polypharmacology at the molecular level, specifically focusing on four 1,2-benzisoxazoles (zonisamide, risperidone, paliperidone, and iloperidone) which have been in clinical use and established as effective therapeutics. Furthermore, an updated and detailed account of the pharmacological properties of 1,2-benzisoxazole derivatives as therapeutics for CNS disorders is described. And finally, outlooks on current issues and future directions in this field are also provided. Results: 1,2-Benzisoxazole was successfully employed in the discovery and development of zonisamide for the treatment of epilepsy and Parkinson’s disease. 1,2- Benzisoxazole is also a significantly important structure for the development of atypical antipsychotics. Conclusion: It is very reasonable to say that 1,2-benzisoxazole is a good example of a privileged structure because it forms the centerpiece of small molecule chemical entities with a wide range of pharmacological properties, especially in the area of CNS disorders.
Keywords: 1, 2-benzisoxazole, privileged structures, polypharmacology, antipsychotics, antiepileptics, Parkinson’s disease.
Current Pharmaceutical Design
Title:1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology
Volume: 22 Issue: 21
Author(s): Yoshikazu Uto
Affiliation:
Keywords: 1, 2-benzisoxazole, privileged structures, polypharmacology, antipsychotics, antiepileptics, Parkinson’s disease.
Abstract: Background: Privileged structures are potentially able to bind to a diverse range of biologically important proteins with high affinities, thus benefiting the discovery of novel bioactive compounds. 1,2-Benxisoxazole derivatives can be such important types of “privileged structures” possessing a rich diversity of biological properties especially in the area of CNS disorders. Methods: This review seeks to explore the most significant examples of 1,2-benzisoxazoles as privileged structures in terms of polypharmacology at the molecular level, specifically focusing on four 1,2-benzisoxazoles (zonisamide, risperidone, paliperidone, and iloperidone) which have been in clinical use and established as effective therapeutics. Furthermore, an updated and detailed account of the pharmacological properties of 1,2-benzisoxazole derivatives as therapeutics for CNS disorders is described. And finally, outlooks on current issues and future directions in this field are also provided. Results: 1,2-Benzisoxazole was successfully employed in the discovery and development of zonisamide for the treatment of epilepsy and Parkinson’s disease. 1,2- Benzisoxazole is also a significantly important structure for the development of atypical antipsychotics. Conclusion: It is very reasonable to say that 1,2-benzisoxazole is a good example of a privileged structure because it forms the centerpiece of small molecule chemical entities with a wide range of pharmacological properties, especially in the area of CNS disorders.
Export Options
About this article
Cite this article as:
Uto Yoshikazu, 1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology, Current Pharmaceutical Design 2016; 22 (21) . https://dx.doi.org/10.2174/1381612822666160224142648
DOI https://dx.doi.org/10.2174/1381612822666160224142648 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Options to Treat Hypertriglyceridaemia
Current Drug Targets Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship?
Current Cardiology Reviews Transfusion-related Acute Lung Injury: An Overview
Current Pharmaceutical Design Cardiometabolic Risk Related to the Association of hypertriglyceridemia-Low HDLc
Current Pharmaceutical Design Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology Food Applications for Flaxseed and its Components: Products and Processing
Recent Patents on Food, Nutrition & Agriculture Women’s Health in Central America: The Complexity of Issues and the Need to Focus on Indigenous Healthcare
Current Women`s Health Reviews Chemical Constituents of Plants from the Genus Valeriana
Mini-Reviews in Organic Chemistry Vitamin E and All-Cause Mortality: A Meta-Analysis
Current Aging Science Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Vascular Pharmacology BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Research on the Pathological Mechanism and Drug Treatment Mechanism of Depression
Current Neuropharmacology Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Obesity in the Childhood: A Link to Adult Hypertension
Current Pharmaceutical Design Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Menopause, A Universal Female Experience: Lessons from Mexico and Central America
Current Women`s Health Reviews Molecular Imaging: Its Application In Cardiovascular Diagnosis
Current Pharmaceutical Design